Tarsus Pharmaceuticals to Host Third Quarter 2026 Financial Results Webcast

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.

Tarsus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Tarsus Pharmaceuticals announced that management will participate in the Guggenheim 3rd Annual Healthcare Conference and the 2026 Jefferies Global Healthcare Conference.

Mizuho Raises Price Target on Tarsus Pharmaceuticals to $102

Mizuho Securities increased its price target for Tarsus Pharmaceuticals from $94 to $102 while maintaining an Outperform rating.

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97

Oppenheimer Raises Price Target on Tarsus Pharmaceuticals to $103

Oppenheimer has increased its price target for Tarsus Pharmaceuticals from $100 to $103 while maintaining an Outperform rating.

Tarsus Pharmaceuticals Reports Third Quarter 2026 Financial Results

Tarsus Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting $194.6 million in net product sales and providing updates on its clinical pipeline.